These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22444272)

  • 1. Correction to "improved coiled-coil design enhances interaction with bcr-abl and induces apoptosis".
    Dixon AS; Miller GD; Bruno BJ; Constance JE; Woessner DW; Fidler TP; Robertson JC; Cheatham TE; Lim CS
    Mol Pharm; 2012 May; 9(5):1535. PubMed ID: 22444272
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.
    Dixon AS; Miller GD; Bruno BJ; Constance JE; Woessner DW; Fidler TP; Robertson JC; Cheatham TE; Lim CS
    Mol Pharm; 2012 Jan; 9(1):187-95. PubMed ID: 22136227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of Bcr-Abl coiled coil oligomerization by design.
    Dixon AS; Pendley SS; Bruno BJ; Woessner DW; Shimpi AA; Cheatham TE; Lim CS
    J Biol Chem; 2011 Aug; 286(31):27751-60. PubMed ID: 21659527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide.
    Bruno BJ; Lim CS
    Mol Pharm; 2015 May; 12(5):1412-21. PubMed ID: 25858426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain.
    Taylor CM; Keating AE
    Biochemistry; 2005 Dec; 44(49):16246-56. PubMed ID: 16331985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.
    Beissert T; Puccetti E; Bianchini A; Güller S; Boehrer S; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
    Blood; 2003 Oct; 102(8):2985-93. PubMed ID: 12829585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
    McWhirter JR; Galasso DL; Wang JY
    Mol Cell Biol; 1993 Dec; 13(12):7587-95. PubMed ID: 8246975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
    Zhang X; Subrahmanyam R; Wong R; Gross AW; Ren R
    Mol Cell Biol; 2001 Feb; 21(3):840-53. PubMed ID: 11154271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.
    Constance JE; Woessner DW; Matissek KJ; Mossalam M; Lim CS
    Mol Pharm; 2012 Nov; 9(11):3318-29. PubMed ID: 22957899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.
    Dixon AS; Constance JE; Tanaka T; Rabbitts TH; Lim CS
    Pharm Res; 2012 Apr; 29(4):1098-109. PubMed ID: 22183511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.
    Beissert T; Hundertmark A; Kaburova V; Travaglini L; Mian AA; Nervi C; Ruthardt M
    Int J Cancer; 2008 Jun; 122(12):2744-52. PubMed ID: 18366061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules.
    Tauchi T; Miyazawa K; Ohyashiki K; Toyama K
    Hum Cell; 1996 Dec; 9(4):333-6. PubMed ID: 9183666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
    Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
    Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
    Woessner DW; Lim CS
    Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules.
    Tauchi T; Miyazawa K; Feng GS; Broxmeyer HE; Toyama K
    J Biol Chem; 1997 Jan; 272(2):1389-94. PubMed ID: 8995449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
    Huang ZL; Gao M; Ji MS; Tao K; Xiao Q; Zhong L; Zeng JM; Feng WL
    Amino Acids; 2013 Feb; 44(2):461-72. PubMed ID: 22782217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R; Porosnicu M; Nguyen D; Worthington E; O'Bryan E; Perkins C; Bhalla K
    Clin Cancer Res; 2001 Feb; 7(2):350-7. PubMed ID: 11234890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells.
    Porosnicu M; Nimmanapalli R; Nguyen D; Worthington E; Perkins C; Bhalla KN
    Leukemia; 2001 May; 15(5):772-8. PubMed ID: 11368438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis.
    Jiang S; Wang X; He Y; Huang H; Cao B; Zhang Z; Liu J; Wang Q; Huang Z; Mao X
    Cell Death Dis; 2021 May; 12(5):456. PubMed ID: 33963175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.